Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Cited by (1,026)

Items 501–600 of 1,026

1. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
   Richard S. Hotchkiss, Elizabeth Colston, Sachin P. Yende, Elliott D. Crouser, Greg S. Martin, Timothy E. Albertson, Raquel R. Bartz, Scott C. Brakenridge, Matthew J. Delano, Pauline K. Park et al. · 2019 · Intensive Care Medicine
2. Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
   Arghya Ray, Deepika Sharma Das, Yan Y. Song, Paul Gerard Guy Richardson, Nikhil C. Munshi, Dharminder Chauhan, Kenneth Carl Anderson · 2015 · Leukemia
3. Cancer stem cells and human malignant melanoma
   T. Schatton, M. Frank · 2007 · Pigment Cell & Melanoma Research
4. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
   Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Zhifei Xu, Xiaochun Yang · 2020 · Drug Design Development and Therapy
5. FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
   Hazem Ghebeh, Eman Barhoush, Asma M. Tulbah, Naser B. Elkum, Taher Al‐Tweigeri, Said Dermime · 2008 · BMC Cancer
6. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection
   Pablo Penaloza‐MacMaster, Alice Oliffson Kamphorst, Andreas Wieland, Koichi Araki, Smita Swaminathan Iyer, Erin E. West, Leigh A. O’Mara, Shu Yang, Bogumila T. Konieczny, Arlene H. Sharpe et al. · 2014 · The Journal of Experimental Medicine
7. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth
   Jonathan Balquiedra Lamano, Jason Balquidera Lamano, Yuping D. Li, Joseph D. DiDomenico, Winward Choy, Dorina Veliceasa, Daniel Eduardo Oyon, Shayan Fakurnejad, Leonel Ampie, Kartik Kesavabhotla et al. · 2019 · Clinical Cancer Research
8. B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts
   Hori, Junko, Wang, Mingcong, Miyashita, Megumi, Tanemoto, Keiko, Takahashi, Hiroshi, Takemori, Toshitada, Okumura, Ko, Yagita, Hideo, Azuma, Miyuki · 2006 · The Journal of Immunology
9. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion
   Bharat K. R. Chaganty, Songbo Qiu, Anneliese M. M. Gest, Yang Lü, Cristina Ivan, George A. Călin, Louis M. Weiner, Zhen Fan · 2018 · Cancer Letters
10. PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
    Zhiqiang Guo, Xin Wang, Dali Cheng, Zhijun Xia, Meng Luan, Shulan Zhang · 2014 · PLoS ONE
11. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
    Christel Devaud, Liza B. John, Jennifer A. Westwood, Phillip Kevin Darcy, Michael H. Kershaw · 2013 · OncoImmunology
12. PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection
    Katsunori Tanaka, Monica J. Albin, Xueli Yuan, Kazuhiro Yamaura, Antje Habicht, Takaya Murayama, Martin R. Grimm, Ana Maria Waaga, Takuya Ueno, Robert F. Padera et al. · 2007 · The Journal of Immunology
13. Combinations of Bevacizumab With Cancer Immunotherapy
    Daniel S. Chen, Herbert I. Hurwitz · 2018 · The Cancer Journal
14. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
    Lussier, Danielle M, Johnson, John L, Hingorani, Pooja, Blattman, Joseph N · 2015 · Journal for ImmunoTherapy of Cancer
15. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
    Miguel F. Sanmamed, Cariad Chester, Ignacio Melero, Holbrook E K Kohrt · 2016 · Annals of Oncology
16. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
    Hao Sun, Si‐Yang Maggie Liu, Jiaying Zhou, Jintian Xu, Huang-Kai Zhang, Hong‐Hong Yan, Jiaojiao Huan, Pingping Dai, Chong‐Rui Xu, Jian Su et al. · 2020 · EBioMedicine
17. The Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity
    Samia Joseph Khoury, Mohamed H. Sayegh · 2004 · Immunity
18. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
    Darryl A. Oble, Robert P. Loewe, Ping Yu, Martín C. Mihm · 2009 · PubMed Central
19. Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
    Stephen R. Goding, Kyle A. Wilson, Ying Xie, Kristina M. Harris, Aparna B. Baxi, Akgül Akpınarlı, Amy M. Fulton, Koji Tamada, Scott Eric Strome, Paul Andrew Antony · 2013 · The Journal of Immunology
20. Neutrophils as active regulators of the immune system in the tumor microenvironment
    Merav E. Shaul, Zvi Gregorio Fridlender · 2017 · Journal of Leukocyte Biology
21. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
    Fabian Finkelmeier, Özge Canli, Andrea Oliver Tal, Thomas Pleli, Jörg Trojan, Michael Schmidt, Bernd Kronenberger, Stefan Zeuzem, Albrecht Piiper, Florian R. Greten et al. · 2016 · European Journal of Cancer
22. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment
    Wen Li, Feifei Li, Xia Zhang, Hui‐Kuan Lin, Chuan Shan Xu · 2021 · Signal Transduction and Targeted Therapy
23. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
    Abhisek Swaika, William A. Hammond, Richard Wayne Joseph · 2015 · Molecular Immunology
24. Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
    Tsvetelina Pentcheva‐Hoang, Emily Corse, James Patrick Allison · 2009 · Immunological Reviews
25. T cell exhaustion: from pathophysiological basics to tumor immunotherapy
    Kemal Catakovic, Eckhard Klieser, Daniel Neureiter, Roland Geisberger · 2017 · Cell Communication and Signaling
26. Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
    Jiawen Cui, Yao Li, Yang Yang, Hai‐Kui Yang, Jia-Mei Dong, Zhi-Hua Xiao, Xin He, Jiahao Guo, Ruiqi L. Wang, Bo Dai et al. · 2024 · Biomedicine & Pharmacotherapy
27. Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes
    Asaka Kondo, Taishi Yamashita, Hideto Tamura, Wanhong Zhao, Takashi Tsuji, Masumi Shimizu, Eiji Shinya, Hidemi Takahashi, Koji Tamada, Lieping Chen et al. · 2010 · Blood
28. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
    Harriet M. Kluger, Christopher R. Zito, Meaghan L. Barr, Marina K. Baine, Veronica Chiang, Mario Sznol, David L. Rimm, Lieping Chen, Lucia B. Jilaveanu · 2015 · Clinical Cancer Research
29. Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity
    Julie Renee Brahmer, Hans J. Hammers, Evan J. Lipson · 2015 · Future Oncology
30. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation
    Vendetti, Frank P., Karukonda, Pooja, Clump, David A., Teo, Troy, Lalonde, Ronald, Nugent, Katriana, Ballew, Matthew, Kiesel, Brian F., Beumer, Jan H., Sarkar, Saumendra N. et al. · 2018 · Journal of Clinical Investigation
31. Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules
    Jeffrey Yang, Longqin Hu · 2018 · Medicinal Research Reviews
32. TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis
    Daniel R. Principe, Brian T. DeCant, Emman Mascariñas, Elizabeth A. Wayne, Andrew M. Diaz, Naomi Akagi, Rosa F. Hwang, Boris Pasche, David W. Dawson, Deyu Fang et al. · 2016 · Cancer Research
33. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
    Jackson G. Egen, Wenjun Ouyang, Lawren C. Wu · 2020 · Immunity
34. <i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
    Sallman, David A., McLemore, Amy F., Aldrich, Amy L., Komrokji, Rami S., McGraw, Kathy L., Dhawan, Abhishek, Geyer, Susan, Hou, Hsin-An, Eksioglu, Erika A., Sullivan, Amy et al. · 2020 · Blood
35. The role of herpesvirus entry mediator as a negative regulator of T cell–mediated responses
    Yang Wang, Sumit Kumar Subudhi, Robert A. Anders, James C. Lo, Yonglian Sun, Sarah E. Blink, Yugang Wang, Jing Hong Wang, Xiaojuan Liu, Karin Mink et al. · 2005 · Journal of Clinical Investigation
36. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway
    Luz-Crawford, Patricia, Noël, Danièle, Fernandez, Ximena, Khoury, Maroun, Figueroa, Fernando, Carrión, Flavio, Jorgensen, Christian, Djouad, Farida · 2012 · PLoS ONE
37. Programmed Cell Death Ligand 1 Expression in Osteosarcoma
    Jacson K. Shen, Gregory Michael Cote, Edwin Choy, Pei Yang, David C. Harmon, Joseph Hasbrouck Schwab, G. Petur Nielsen, Ivan A. Chebib, Soldano Ferrone, Xinhui Wang et al. · 2014 · Cancer Immunology Research
38. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
    Chun‐Te Wu, Wen‐Cheng Chen, Ying‐Hsu Chang, Wei‐Yu Lin, Miao‐Fen Chen · 2016 · Scientific Reports
39. Immune Resistance in Lung Adenocarcinoma
    Μάγδα Σπέλλα, Georgios T. Stathopoulos · 2021 · Cancers
40. A comprehensive review of immune checkpoint inhibitors for cancer treatment
    Md Aslam Hossain · 2024 · International Immunopharmacology
41. B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1
    Margaret Greene Petroff, Lieping Chen, Teresa A. Phillips, Dagmar Azzola, Peter Sedlmayr, Joan S. Hunt · 2003 · Biology of Reproduction
42. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
    Michael Hettich, Friederike Braun, Mark Daniel Bartholomä, Reinhold Schirmbeck, Gabriele Niedermann · 2016 · Theranostics
43. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
    Young‐Jun Park, Da‐Sol Kuen, Yeonseok Chung · 2018 · Experimental & Molecular Medicine
44. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
    Gaopeng Li, Ilona Kryczek, Jutaek Nam, Xiong Li, Shasha Li, Jing Li, Shuang Wei, Sara Grove, Linda Vatan, Jiajia Zhou et al. · 2021 · Nature Cell Biology
45. Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
    Partha Sarathi Chowdhury, Kenji Chamoto, Tasuku Honjo · 2017 · Journal of Internal Medicine
46. Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy
    Bojun Wang, Tian Tian, Karl‐Henning Kalland, Xisong Ke, Yi Qu · 2018 · Trends in Pharmacological Sciences
47. GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages
    Jinhong Chen, Zhifei Lin, Lu Liu, Rui Zhang, Yan Geng, Ming-Hao Fan, Wenwei Zhu, Ming Lü, Lu Lu, Huliang Jia et al. · 2021 · Signal Transduction and Targeted Therapy
48. Soluble CD276 (B7‐H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum
    Guangbo Zhang, Jianquan Hou, Jinfang Shi, Gehua Yu, Binfeng Lu, Xueguang Zhang · 2008 · Immunology
49. Dual blockade of CXCL12‐CXCR4 and PD‐1–PD‐L1 pathways prolongs survival of ovarian tumor–bearing mice by prevention of immunosuppression in the tumor microenvironment
    Yang C. Zeng, Binghao Li, Yingying Liang, Patrick M. Reeves, Xiying Qu, Chongzhao Ran, Qiuyan Liu, Michael V. Callahan, Ann E. Sluder, Jeffrey A. Gelfand et al. · 2019 · The FASEB Journal
50. Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
    Betty Li, Melinda J. VanRoey, Changyu Wang, Tseng-hui Timothy Chen, Alan J. Korman, Karin U. Jooss · 2009 · Clinical Cancer Research
51. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
    Shinsuke Nakao, Yukinori Arai, Mamoru Tasaki, Midori YAMASHITA, Ryuji Murakami, Tatsuya Kawase, Nobuaki Amino, Motomu Nakatake, Hajime Kurosaki, Masamichi Mori et al. · 2020 · Science Translational Medicine
52. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models
    Marcel André Schneider, Laura Heeb, Michał Beffinger, Stanislav Pantelyushin, Michael Linecker, Lilian Roth, Kuno Lehmann, U. Ungethüm, Sebastian Kobold, Rolf Graf et al. · 2021 · Science Translational Medicine
53. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
    Phillips, Therese, Simmons, Pauline, Inzunza, Hector D., Cogswell, John, Novotny, James, Taylor, Clive, Zhang, Xiaoling · 2015 · Applied Immunohistochemistry &amp; Molecular Morphology
54. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    Sergio A. Quezada, Karl S. Peggs · 2013 · British Journal of Cancer
55. Epigenetics and immunotherapy: The current state of play
    Jennifer Dunn, Sudha Rao · 2017 · Molecular Immunology
56. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
    Tae Kon Kim, Roy S. Herbst, Lieping Chen · 2018 · Trends in Immunology
57. Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
    Andreas Due Ørskov, Marianne Bach Treppendahl, Anni Skovbo, Mette Skov Holm, Lone Smidstrup Friis, Marianne Hokland, Kirsten Grønbæk · 2015 · Oncotarget
58. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
    Karishma R. Rajani, Christopher Parrish, Timothy J. Kottke, Jill Thompson, Shane Zaidi, Elizabeth J. Ilett, Kevin G. Shim, Rosa María Díaz, Hardev Pandha, Kevin Joseph Harrington et al. · 2015 · Molecular Therapy
59. The role of B7 family molecules in hematologic malignancy
    Paul Greaves, John G. Gribben · 2012 · Blood
60. The New B7s: Playing a Pivotal Role in Tumor Immunity
    Dallas B. Flies, Lieping Chen · 2007 · Journal of Immunotherapy
61. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis
    Haidong Dong, Scott Eric Strome, Eric L. Matteson, Kevin G. Moder, Dallas B. Flies, Gefeng Zhu, Hideto Tamura, Colin L. W. Driscoll, Lieping Chen · 2003 · Journal of Clinical Investigation
62. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
    Allison M. Martin, Thomas R. Nirschl, Christopher J. Nirschl, Brian J. Francica, Christina M. Kochel, Adrie van Bokhoven, Alan Keith Meeker, Marshall Scott Lucia, Robert A. Anders, A M DeMarzo et al. · 2015 · Prostate Cancer and Prostatic Diseases
63. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
    Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew Eugene Hendifar, Richard Tuli · 2018 · Journal for ImmunoTherapy of Cancer
64. Oscillating CD8+ T Cell Effector Functions after Antigen Recognition in the Liver
    Isogawa, Masanori, Furuichi, Yoshihiro, Chisari, Francis V. · 2005 · Immunity
65. Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor
    Megan E. Prosser, Christine E. Brown, Andrew F. Shami, Stephen J. Forman, Michael C. Jensen · 2012 · Molecular Immunology
66. The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy
    Asís Palazón, Iván Martínez‐Forero, Álvaro Teijeira, Aizea Morales‐Kastresana, Carlos Alfaro, Miguel F. Sanmamed, José Luis Perez‐Gracia, Iván Peñuelas, Sandra Hervás‐Stubbs, Ana Rouzaut et al. · 2012 · Cancer Discovery
67. Autophagy inhibition enhances PD-L1 expression in gastric cancer
    Xiaojuan Wang, William Ka Kei Wu, Jing Gao, Zhongwu Li, Bin Dong, Xiaoting Lin, Yilin Li, Yanyan Li, Jifang Gong, Changsong Qi et al. · 2019 · Journal of Experimental & Clinical Cancer Research
68. Role of the Programmed Death-1 Pathway in Regulation of Alloimmune Responses In Vivo
    Sigrid E. Sandner, Michael R. Clarkson, Alan David Salama, Alberto Sanchez Fueyo, Christoph M. Domenig, Antje Habicht, Nader Najafian, Hideo Yagita∥, Miyuki Azuma, Laurence A. Turka et al. · 2005 · The Journal of Immunology
69. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
    Chamoto, Kenji, Yaguchi, Tomonori, Tajima, Masaki, Honjo, Tasuku · 2023 · Nature Reviews Immunology
70. Schistosoma mansoni Worms Induce Anergy of T Cells via Selective Up-Regulation of Programmed Death Ligand 1 on Macrophages
    Philip Smith, Caitríona M. Walsh, Niamh E. Mangan, Rosie E. Fallon, Jon R. Sayers, Andrew N. J. McKenzie, Padraic G. Fallon · 2004 · The Journal of Immunology
71. Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
    Yayi He, Christopher J. Rivard, Leslie M. Rozeboom, Hui Yu, Kim E. Ellison, Ashley A. Kowalewski, Caicun Zhou, Fred R. Hirsch · 2016 · Cancer Science
72. Endoplasmic reticulum stress‐induced exosomal miR‐27a‐3p promotes immune escape in breast cancer via regulating PD‐L1 expression in macrophages
    Xiaoli Yao, Yi Tu, Yulin Xu, Yueyue Guo, Feng Yao, Xinghua Zhang · 2020 · Journal of Cellular and Molecular Medicine
73. PD-1 expression on dendritic cells suppresses CD8⁺T cell function and antitumor immunity
    Lim, Tong Seng, Chew, Valerie, Sieow, Je Lin, Goh, Siting, Yeong, Joe Poh-Sheng, Soon, Ai Ling, Ricciardi-Castagnoli, Paola · 2016 · OncoImmunology
74. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
    Naval Guastad Daver, Prajwal Chaitanya Boddu, Guillermo Garcia‐Manero, Shalini Singh Yadav, Padmanee Sharma, James Patrick Allison, Hagop M. Kantarjian · 2018 · Leukemia
75. Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells
    Karl Egan, Darragh Crowley, Paul C Smyth, Sharon A. O’Toole, Cathy D. Spillane, Cara M. Martin, Michael F. Gallagher, Aoife Canney, Lucy Norris, Niamh Conlon et al. · 2011 · PLoS ONE
76. Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy
    Panpan Zhang, Yuanyuan Ma, Chao Lv, Miao Huang, Mingzhen Li, Bin Dong, Xijuan Liu, Guo An, Wenlong Zhang, Jianzhi Zhang et al. · 2016 · Cancer Science
77. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
    Crane, C A, Panner, A, Murray, J C, Wilson, S P, Xu, H, Chen, L, Simko, J P, Waldman, F M, Pieper, R O, Parsa, A T · 2009 · Oncogene
78. Expression of B7-H1 on Gastric Epithelial Cells: Its Potential Role in Regulating T Cells during Helicobacter pylori Infection
    Soumita Das, Giovanni Suárez, Ellen J. Beswick, Johanna C. Sierra, David Yates Graham, Victor E. Reyes · 2006 · The Journal of Immunology
79. Immunomodulation by ionizing radiation—impact for design of radio‐immunotherapies and for treatment of inflammatory diseases
    Benjamin Frey, Michael Rückert, Lisa Deloch, Paul F. Rühle, Anja Derer, Rainer Fietkau, Udo S. Gaipl · 2017 · Immunological Reviews
80. Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
    Yibo Yin, Alina C. Boesteanu, Zev A. Binder, Chong Bing Xu, Reiss A. Reid, Jesse L. Rodriguez, Danielle R. Cook, Radhika Thokala, Kristin Blouch, Bevin McGettigan-Croce et al. · 2018 · Molecular Therapy — Oncolytics
81. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
    David, Justin M., Dominguez, Charli, McCampbell, Kristen K., Gulley, James L., Schlom, Jeffrey, Palena, Claudia · 2017 · OncoImmunology
82. Immunotherapies: Exploiting the Immune System for Cancer Treatment
    Jeffrey Koury, Mariana Lucero, Caleb Cato, Lawrence Chang, Joseph Geiger, Denise Henry, Jennifer Hernandez, Fion Hung, Preet Kaur, Garrett Teskey et al. · 2018 · Journal of Immunology Research
83. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
    Samantha R. Ellis, Aren T Vierra, Jillian Wong Millsop, Mario E. Lacouture, Maija H. Kiuru · 2020 · Journal of the American Academy of Dermatology
84. Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
    Miguel F. Sanmamed, Lieping Chen · 2014 · The Cancer Journal
85. Immunology beats cancer: a blueprint for successful translation
    Drew M. Pardoll · 2012 · Nature Immunology
86. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
    Lei Lü, Xiaobing Xu, Bin Zhang, Rongsheng Zhang, Hongzan Ji, Xuan Wang · 2014 · Journal of Translational Medicine
87. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status
    Su‐Jin Shin, Yoon Kyung Jeon, Pil-Jong Kim, Yong Mee Cho, Jaemoon Koh, Doo Hyun Chung, Heounjeong Go · 2015 · Annals of Surgical Oncology
88. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
    Jacqueline Fontugne, Jérémy Augustin, Anaïs Pujals, Philippe Compagnon, Benoı̂t Rousseau, Alain Luciani, Christophe Tournigand, Daniel Cherqui, Daniel Azoulay, Jean–Michel Pawlotsky et al. · 2017 · Oncotarget
89. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
    Jian Qiao, Zhida Liu, Chunbo Dong, Yan Luan, Anli Zhang, Casey Moore, Kai Fu, Jianjian Peng, Yang Wang, Zhenhua Ren et al. · 2019 · Cancer Cell
90. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1
    Dan Zhu, Ruidan Xu, Xinping Huang, Zefang Tang, Yonglu Tian, Jinfang Zhang, Xiaofeng Zheng · 2020 · Cell Death and Differentiation
91. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
    Yi Qing, Qing Li, Tao Ren, Wei Xia, Yu Peng, Gao lei Liu, Hao Luo, Yuxing Yang, Xiao Yan Dai, Shufeng Zhou et al. · 2015 · Drug Design Development and Therapy
92. Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
    Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Kazuhiko Yamada, Yohei Imamura, Takaaki Tokito, Takashi Kinoshita, Masayoshi Kage, Tomoaki Hoshino · 2014 · Journal of Thoracic Oncology
93. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
    Liang Wang, Hua Wang, Hao Chen, Wei-da Wang, Xiao-qin Chen, Qi-rong Geng, Zhong-Jun Xia, Yue Lu · 2015 · Oncotarget
94. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis
    Aurore Saudemont, Bruno Quesnel · 2004 · Blood
95. PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
    Alexander W. Macfarlane, Mowafaq Jillab, Elizabeth R. Plimack, Gary R. Hudes, Robert G. Uzzo, Samuel Litwin, Essel Dulaimi, Tahseen Al‐Saleem, Kerry S. Campbell · 2013 · Cancer Immunology Research
96. Emerging targeted agents in metastatic breast cancer
    Dimitrios Zardavas, Jose M Baselga, Martine J Piccart · 2013 · Nature Reviews Clinical Oncology
97. Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma
    Sheila F. Faraj, Enrico Munari, Güneş Güner, Janis Marie Taube, Robert A. Anders, Jessica L Hicks, Alan Keith Meeker, Mark Schoenberg, Trinity Jude Bivalacqua, Charles G. Drake et al. · 2015 · Urology
98. PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface
    Apoorvi Chaudhri, Yanping Xiao, Alyssa N. Klee, Xiaoxu Wang, Baogong Zhu, Gordon James Freeman · 2018 · Cancer Immunology Research
99. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
    Xin Chen, Xiaomin Song, Kang Li, Tong Zhang · 2019 · Frontiers in Immunology
100. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
     Shixiang Wang, Li An Cowley, Xuesong Liu · 2019 · Molecules